A Single-Dose Pharmacokinetic Study of Eloralintide in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function
J3R-MC-YDAH
Phase 1 other active
Quick answer
A Single-Dose Pharmacokinetic Study of Eloralintide in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function for Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function
- Phase
- Phase 1
- Modality
- other
- Status
- active